Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 540702 | NSE Symbol : LASA | ISIN : INE670X01014 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
05-Feb-2025	13-Feb-2025	Quarterly Results	Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation 2015 notice is hereby given that Meeting of the Board of Directors of the Company is scheduled to be held on Thursday February 13 2025 inter alia; 1. To consider approve and take on records unaudited financial results of the Company along with the Limited Review Report for the quarter ended on December 31 2024. 2. To discuss any other matter with the permission of the Chairperson. In accordance with the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015 and Companys Code of Conduct the Trading Window shall continue to remain closed till 48 hours after the declaration of the unaudited financial results of the Company for the quarter ended December 31 2024. Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 02.00 p.m. and concluded at 06.00 p.m. inter- alia have considered and approved the following: 1. The statement of unaudited Financial Results of the Company for the quarter ended on December 31, 2024. 2. Limited Review Report from Statutory Auditor for the quarter ended on December 31, 2024. (As Per BSE Announcement Dated on: 13/02/2025)
22-Jan-2025	28-Jan-2025	Issue of Warrants	Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation 2015 notice is hereby given that Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday January 28 2025 inter alia; 1. To consider approve finalize the issue of warrants and price of warrants convertible into equity shares / or equity shares to be issued on preferential basis in accordance with the provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 (SEBI ICDR Regulations). 2. To consider approve finalize the proposal of fund raising by way of equity shares through rights issue in accordance with the provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 (SEBI ICDR Regulations) as permitted under applicable law subject to such regulatory/statutory approvals as may be required. 3. Any other matter with the permission of chair. Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 02.00 P.M. and concluded at 03.45 P.M. (As Per BSE Announcement Dated on: 28/01/2025)
20-Jan-2025	24-Jan-2025	EGM	Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2025 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation, 2015 notice is hereby given that Meeting of the Board of Directors of the Company is scheduled to be held on Friday, January 24, 2025, inter alia; 1. To consider, approve, finalize the issue of warrants and price of warrants convertible into equity shares / or equity shares to be issued on preferential basis in accordance with the provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (SEBI ICDR Regulations). 2. To consider and approve draft notice of Extra -ordinary General Meeting. 3. Any other matter with the permission of chair. The Board Meeting to be held on 24/01/2025 Stands Cancelled. (As per BSE Announcement Dated on 22/01/2025)
06-Nov-2024	14-Nov-2024	Quarterly Results	Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve 1. To consider approve and take on records unaudited financial results of the Company along with the Limited Review Report for the quarter and half year ended on September 30 2024. 2. To discuss any other matter with the permission of the Chairperson. In accordance with the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015 and Companys Code of Conduct the Trading Window shall continue to remain closed till 48 hours after the declaration of the unaudited financial results of the Company for the quarter and half year ended September 30 2024. This Intimation is also available on the companys website at www.lasalabs.com and on the website of the stock Exchange at www.bseindia.com and www.nseindia.com . Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 01.30 p.m. and concluded at 06.15 p.m. inter- alia have considered and approved the following: 1. The statement of unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2024. 2. Limited Review Report from Statutory Auditor for the quarter ended on September 30, 2024. (As Per BSE Announcement Dated on: 14/11/2024)
03-Sep-2024	03-Sep-2024	AGM	considered and approved the following: 1) The Notice of the Nineth (9th) Annual general Meeting (AGM) of the Company 2) The 9th AGM is scheduled to be held on Friday, September 27, 2024 at 09.30 A.M. through Video conferencing (VC) / Other Audio-Visual means (OAVM). 3) The Director's Report of the Company together with Report on Corporate Governance, Management Discussion and Analysis Report and other relevant annexures & Schedules thereto for the financial year ended March 31, 2024. 4) Appointment of Shravan A. Gupta & Associates, Practicing Company Secretaries as a scrutinizer for 9th Annual General Meeting. 5) Re-Appointment of Mr. Omkar Herlekar (DIN: 01587154), Director who is liable to retire by rotation and eligible for re-appointment. 6) To close Register of Members and Share Transfer Books of the Company from Thursday 21st September 2024 to Friday 27th September 2024 both days inclusive.
06-Aug-2024	14-Aug-2024	Quarterly Results	Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation 2015 notice is hereby given that Meeting of the Board of Directors of the Company is scheduled to be held on Wednesday August 14 2024 inter alia; 1. To consider approve and take on records unaudited financial results of the Company along with the Limited Review Report from the Statutory Auditor for the quarter ended on June 30 2024. 2. To discuss any other matter with the permission of the Chairperson. In accordance with the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015 and Companys Code of Conduct the Trading Window shall continue to remain closed till 48 hours after the declaration of the unaudited financial results of the Company for the quarter ended June 30 2024. Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 01.30 p.m. and concluded at 04.30 p.m. inter- alia have considered and approved the following: 1. The statement of unaudited Financial Results of the Company for the quarter ended on June 30, 2024. 2. Limited Review Report from Statutory Auditor for the quarter ended on June 30, 2024. (As Per Bse Announcement Dated on 14.08.2024)
24-May-2024	30-May-2024	Accounts	Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation 2015 notice is hereby given that Meeting of the Board of Directors of the Company is scheduled to be held on Thursday May 30 2024 inter alia; 1. To consider approve and take on records Audited financial results of the Company for the quarter and the year ended March 31 2024. 2. To discuss any other matter with the permission of the Chairperson. Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 8.00 p.m. and concluded at 10.45 p.m. inter- alia have considered and approved the following: The statement of Audited Financial Results of the Company for the quarter and the financial year ended on March 31, 2024 A copy of the statement of audited Financial Results, Cash Flow statement along with Audited Report submitted by the Statutory Auditors of the Company is attached herewith. (As Per BSE Announcement Dated on 30.05.2024)
08-Mar-2024	08-Mar-2024	Change in Directors	Pursuant to Regulation 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 2.00 p.m. and concluded at 3.00 p.m. inter- alia have considered and approved the following: 1. Appointment of Mr. Umesh Pawar as an Additional Director (Executive Director) of the Company. Further the aforesaid appointment shall be subject to approval of members at the ensuing General Meeting/ Postal Ballot of the Company. Revised outcome of Board Meeting March 08, 2024 Pursuant to Regulation 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held on March 08, 2024 which was commenced at 2.00 p.m. and concluded at 3.00 p.m. inter- alia have considered and approved the following: 1. Appointment of Mr. Umesh Pawar (DIN: 10539778) as an Additional Director (Executive Director) of the Company and he shall be designated as Whole-time Director of the Company for a term of 5 (five) years with effect from March 08, 2024, subject to the approval of shareholders at General Meeting of the Company.. We are enclosing herewith the brief details of the aforesaid change as prescribed under SEBI Listing Regulations read with SEBI circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as Annexure I. (As per BSE Announcement Dated on 11/03/2024)
05-Feb-2024	13-Feb-2024	Quarterly Results	Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation 2015 notice is hereby given that Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday February 13 2024 1. To consider approve and take on records unaudited financial results of the Company along with the Limited Review Report from the Statutory Auditor for the quarter ended on December 31 2023. 2. To discuss any other matter with the permission of the Chairperson. Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 4.00 p.m. and concluded at 6.15 p.m. inter- alia have considered and approved the following: 1. The statement of unaudited Financial Results of the Company for the quarter ended on December 31, 2023. 2. Limited Review Report from Statutory Auditor for the quarter ended on December 31, 2023. (As Per BSE Announcement dated on 13.02.2024)
04-Nov-2023	10-Nov-2023	Quarterly Results	Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation 2015 notice is hereby given that Meeting of the Board of Director of the Company is scheduled to be held on Friday November 10 2023 Pursuant to Regulation 29 and 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015, we would like to inform you that the Board of Director in their Meeting Held Today which was Commenced at 3.00 PM and Concluded at 05.15 P.M. (As Per BSE Announcement dated on 10.11.2023)
07-Aug-2023	14-Aug-2023	Quarterly Results	Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2023 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation 2015 notice is hereby given that Meeting of the Board of Director of the Company is scheduled to be held on Monday August 14 2023 inter alia; To consider approve and take on records unaudited financial results of the Company for the quarter ended June 30 2023. To discuss any other matter with the permission of the Chairperson Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 1.00 p.m. and concluded at 6.30 p.m. inter- alia have considered and approved the following: 1. The statement of unaudited Financial Results of the Company for the quarter ended on June 30, 2023 2. Limited Review Report from Statutory Auditor for the quarter ended on June 30, 2023 3. The appointment of M/s. Gupta Rustagi & Co Chartered Accountant is subject to the approval of the Shareholders of the Company at the ensuing AGM. M/s Thanawala & Co., Chartered Accountants (FRN: 110948W), the present Statutory Auditors of the Company will complete their term at the conclusion of the ensuing 8th AGM of the Company. (As per BSE Announcement Dated on 14/08/2023)
22-May-2023	09-Jun-2023	Accounts	Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2023 inter alia to consider and approve Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation 2015 notice is hereby given that Meeting of the Board of Director of the Company is scheduled to be held on Monday May 29 2023 1. To consider approve and take on records Audited financial results of the Company for the quarter and year ended March 31 2023. 2. To discuss any other matter with the permission of the Chairperson. The Board Meeting to be held on 29/05/2023 has been revised to 07/06/2023 The Board Meeting to be held on 29/05/2023 has been revised to 07/06/2023 (As per BSE Announcement Dated on 27/05/2023) Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/06/2023 ,inter alia, to consider and approve Board Meeting which was supposed to be held today has been rescheduled to Friday June 09, 2023, since the consolidation of books of Harishree Aromatics and Chemicals Pvt Ltd on account of Amalgamation could not be completed on time (As per BSE Announcement Dated on 07/06/2023) Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 12.00 p.m. and concluded at 04.30 p.m 1. The Audited Financial Results of the Company for the Quarter and financial Year ended March 31, 2023 (As per BSE Announcement Dated on 09/06/2023)
21-Mar-2023	21-Mar-2023	Change in Other Executives	Pursuant to Regulation 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 12:00 Noon and concluded at 02:00 p.m. inter- alia has considered and approved the following:. On the recommendation of the Nomination and Remuneration committee the Board approved the Appointment of Mrs. Mitti Jain as Company Secretary & Compliance Officer of the company w.e.f March 21, 2023 as per the provisions of Section 203 of the Companies Act 2013 Mrs. Mitti Jain will be the Key Managerial Personnel of the Company.
06-Feb-2023	14-Feb-2023	Quarterly Results	Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation 2015 notice is hereby given that Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday February 14 2023 to consider approve and take on record Un-audited financial results along with limited review report for the quarter ended December 31 2022 and / or to discuss and any other business / matter with the permission of chair we would like to inform you that the Board of Directors in their meeting held today which was commenced at 3.30 p.m. and concluded at 5.00 p.m. inter- alia have considered and approved the following: 1. The statement of unaudited Financial Results of the Company for the quarter ended on December 31, 2022. 2. Limited Review Report from Statutory Auditor for the quarter ended on December 31, 2022. (As Per BSE Announcement Dated on 14.02.2023)
08-Nov-2022	14-Nov-2022	Quarterly Results	Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 inter alia to consider and approve and take on record Un-audited financial results along with limited review report for the quarter and half year ended September 30 2022 and / or to discuss and any other business / matter with the permission of chair. Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 2.00 p.m. and concluded at 3.30 p.m. inter- alia have considered and approved the following: 1. The statement of unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2022. 2. Limited Review Report from Statutory Auditor for the quarter and half year ended on September 30, 2022. (As Per BSE Announcement Dated on 14.11.2022)

1 2

LOGIN HERE

Lasa Supergenerics Ltd

Board Meeting